NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Akanda Corp. (AKAN) Stock Analysis

Akanda Corp. (AKAN) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

AKAN

$1.12

+$0.04 (+3.70%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AKAN with… →

AKAN Key Statistics

As of Oct 21, 2026

Trading

Open: $1.08
Previous Close: $1.08
Day's Range: 1.00–1.13
52-Week Range: 1.00–78.90
Volume: 1.31M

Valuation

Market Cap: $2.96M
P/S ratio: 4.46

Financials (FY)

Revenue (FY): $258.08K
Net Income (FY): −$45.65M
Shares Outstanding: 2.39M
1-Year Return: −97.74%

Dividend and dates

Avg Volume: 1.36M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, AKAN closed at $1.12, −97.74% over 1 year.

Akanda Corp. (AKAN) has a market capitalization of $2.96M.

In fiscal 2025, AKAN reported revenue of $258.08K.

AKAN Stock Return by Calendar Year

Akanda Corp. (AKAN) return since Mar 2022: what $10,000 became

1 year: $10,000 $226; −97.74%
3 years: $10,000 $4; −99.96%
Since Mar 2022: $10,000 $0.02; −99.9998%

If you had invested $10,000 in Akanda Corp. (AKAN) at the close on March 15, 2022, the earliest close on record here, it would have been worth $0.02 at the close on October 21, 2026: −99.9998% in total, −94.29% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−98.58%−70.47%−95.45%−90.86%−89.12%

2022*2023202420252026*

Year	Return
2026 (partial year)	−89.12%
2025	−90.86%
2024	−95.45%
2023	−70.47%
2022 (partial year)	−98.58%

As of October 21, 2026.

AKAN Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$258.08K	−$45.65M	−17,690.2%
2024	$0.00	−$4.10M	—
2023	$423.68K	−$32.28M	−7,617.7%
2022	$2.62M	−$11.66M	−445.0%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$258.08K	−$156.02K	−$4.98M	−$45.65M	−17,690.2%
2024	$0.00	$0.00	−$4.03M	−$4.10M	—
2023	$423.68K	$59.34K	−$3.66M	−$32.28M	−7,617.7%
2022	$2.62M	$3.27M	−$20.18M	−$11.66M	−445.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AKAN Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks

Metric	AKAN	Drug Manufacturers - Specialty & Generic median	vs median
P/S ratio	4.46	2.10	113% above

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Akanda Corp. (AKAN) is capitalised at $2.96M on the latest close. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry.

The 52-week range on file runs from $1.00 to $78.90. AKAN last closed at $1.12 on October 21, 2026. That is +$0.04 (+3.70%) against the previous close. The latest close sits 12% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $258.08K. The same year closed with a net loss of $45.65M.

Across the 4 fiscal years on file, revenue moves from $2.62M in 2022 to $258.08K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

Measured against sales, the shares trade at 4.46 times revenue. On price-to-sales that is 112.5% above the Drug Manufacturers - Specialty & Generic median of 2.1. The medians here are taken across 97 Drug Manufacturers - Specialty & Generic companies that report the metric.

Annualized volatility over the trailing 4 years is 186.56%. Over the trailing twelve months the total return is −97.74%. Measured over 3 years, that is −92.69% a year compounded.

Growth & Income

No dividend is on file for AKAN.

The strongest complete calendar year on file is 2023 at −70.47%; the weakest is 2024 at −95.45%. Of the 3 complete calendar years on file, 0 finished higher. 2026 is still running; the total return is −89.12% year to date.

Peer Comparison

Akanda Corp. (AKAN) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Akanda Corp.	AKAN	$2.96M	—
Takeda Pharmaceutical Company Limited	TAK	$63.67B	—
Teva Pharmaceutical Industries Limited	TEVA	$47.37B	67.7
Haleon plc	HLN	$44.06B	20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Akanda Corp. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

TEVA

Teva Pharmaceutical Industries Limited

$47.37B

HLN

Haleon plc

$44.06B

ZTS

Zoetis Inc.

$32.90B

UTHR

United Therapeutics Corporation

$24.17B

VTRS

Viatris Inc.

$21.19B

View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About Akanda Corp.

Akanda Corp., through its subsidiaries, operates as early-stage cannabis company in Mexico. It is involved in medical cannabis cultivation, manufacturing, and sale; and leasing and/or rental of fiber optic networks and telecommunication towers. The company is based in Toronto, Canada.

Visit website →